MedTrace Logo

Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study

NCT01006941 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2011-11-10

No results posted yet for this study

Summary

The hypothesis of this study is that treatment with Trichuris suis ova will be safe and effective as an oral treatment of patients with relapsing multiple sclerosis.

Conditions

Interventions

BIOLOGICAL

Trichuris suis ova

2500 ova per dose, orally, every second week, during 12 weeks

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Statens Serum Institut

    collaborator OTHER

  • Copenhagen University Hospital, Hvidovre

    collaborator OTHER

  • OvaMed GmbH

    collaborator INDUSTRY

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Per S Sørensen, Professor · Rigshospitalet, Danish Multiple Slerosis Research Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-01-31
Completion
2011-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01006941 on ClinicalTrials.gov